BUZZ-Progyny slides after trimming annual forecasts, Q3 rev miss

Reuters11-14

** Fertility benefits management firm Progyny's shares fall 18.6% to $14

** Earlier in the session, PGNY hit $13.78 — lowest since its debut in Oct 2019

** Co forecasts annual rev of $1.135 bln to $1.150 bln, lower than previous expectation of $1.17 bln to $1.20 bln

** Forecasts FY adj. EPS between $1.54 and $1.57 vs earlier est of $1.53 to $1.61

** Expects Q4 rev of $266.2 mln to $281.2 mln and adj. EPS of 31 cents to 35 cents

** Co reported Q3 rev of $286.63 mln, missing est of $296.88 mln - LSEG

** Co says customers took longer to progress through their treatments, and so, took fewer treatments overall

** At least 4 brokerages cut PT on stock

** Leerink Partners cuts PT to $17 from $21, says biggest concern remains how visibility into the business remains challenged

** BofA Global Research cuts PT to $21 from $22

** Including session's move, stock down 62.3% YTD

(Reporting by Sukriti Gupta in Bengaluru)

((Sukriti.Gupta@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment